HDFC Pharma and Healthcare Fund Regular Growth
- Sector - Healthcare
- Equity
- Very High Risk
Explore On
Rating:
Key Metrics
Aum
₹2,158.58 Cr
Expense Ratio
1.99%
Exit Load
1.00%
Min. Investment
₹100.00
Min. SIP
₹100.00
Launch Date
4 Oct 2023
CAGR Returns
| Period | Absolute(%) | Annualised(%) |
|---|---|---|
| 1 Month | +2.13% | -- |
| 3 Months | +11.33% | -- |
| 6 Months | +14.21% | -- |
| 1 Year | +19.26% | +19.26% |
| 2 Years | -- | +22.87% |
| 3 Years | -- | 0% |
| 5 Years | -- | 0% |
| Since Launch | +95.88% | +28.54% |
Holdings as on 9 June 2026
| Name | Value (₹Cr) | Holding % |
|---|---|---|
| Divi's Laboratories | 184.73 | 8.56 |
| Sun Pharmaceutical Industries | 173.79 | 8.05 |
| Lupin | 131.00 | 6.07 |
| Glenmark Pharmaceuticals | 130.87 | 6.06 |
| Max Healthcare Institute | 127.98 | 5.93 |
| Aster DM Healthcare | 117.85 | 5.46 |
| Alkem Laboratories | 101.25 | 4.69 |
| Anthem BioSciences | 98.18 | 4.55 |
| IPCA Laboratories | 94.66 | 4.39 |
| Cipla | 92.18 | 4.27 |
Morning Star Rating
Rating:
Risk
Return
Risk & Volitility
0.00
Sharpe Ratio
0.00%
Std. Deviation
--
Tracking Error
--
Alpha
--
Beta
Peer Comparison
| Fund Name | 1Y | 3Y | 5Y |
|---|---|---|---|
| UTI Healthcare Fund Regular Plan Growth | +10.05% | +25.81% | +13.76% |
| Mirae Asset Healthcare Fund Regular Growth | +12.49% | +24.53% | +14.01% |
| DSP Healthcare Fund Regular Growth | +7.68% | +21.85% | +14.03% |
| Tata India Pharma & Healthcare Fund Regular Growth | +5.24% | +21.75% | +13.02% |
| HDFC Pharma and Healthcare Fund Regular Growth | +19.26% | -- | -- |
Results are calculated on CAGR basis
About Fund
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
The HDFC Pharma and Healthcare Fund Regular Growth has an AUM of 2158.58 crores & has delivered CAGR of 0.00 in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.99%. The minimum investment in HDFC Pharma and Healthcare Fund Regular Growth is Rs 100 and the minimum SIP is Rs 100.
As per morningstar the risk & return rating of the fund are Medium & Exceptional respectively.
The fund has a present cash holding of %. The top holdings of the fund include Divi's Laboratories, Sun Pharmaceutical Industries, Lupin, Glenmark Pharmaceuticals.
The major sectors where the fund is invested are Biotechnology & Drugs, Healthcare Facilities, Chemical Manufacturing, Major Drugs.
Some of the similar funds are UTI Healthcare Fund Regular Plan Growth, Mirae Asset Healthcare Fund Regular Growth, DSP Healthcare Fund Regular Growth, Tata India Pharma & Healthcare Fund Regular Growth, HDFC Pharma and Healthcare Fund Regular Growth. HDFC Pharma and Healthcare Fund Regular Growth has a sharpe ratio of 0.00 & a standard deviation of 0.00%.
FAQs
According to the morning star rating HDFC Pharma and Healthcare Fund Regular Growth has a Medium risk & Exceptional return.
HDFC Pharma and Healthcare Fund Regular Growth is managed by Dhruv Muchhal,Nikhil Mathur.
The expense ratio of HDFC Pharma and Healthcare Fund Regular Growth is 1.99%.
The 5 year annualized return on HDFC Pharma and Healthcare Fund Regular Growth is 0.00% & it has generated 19.26% in the last 1 year.
The minimum investment in HDFC Pharma and Healthcare Fund Regular Growth is 100 Rs.
HDFC Pharma and Healthcare Fund Regular Growth has an AUM of 2158.58 crores.
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.